Wall Street Zen downgraded shares of Bioventus (NASDAQ:BVS - Free Report) from a strong-buy rating to a buy rating in a report issued on Friday.
Bioventus Trading Up 0.6%
NASDAQ BVS traded up $0.04 during trading on Friday, reaching $6.30. 238,071 shares of the company's stock traded hands, compared to its average volume of 463,195. The company has a debt-to-equity ratio of 1.66, a quick ratio of 0.89 and a current ratio of 1.43. The company has a market capitalization of $517.48 million, a price-to-earnings ratio of -13.12 and a beta of 0.84. Bioventus has a 12-month low of $6.02 and a 12-month high of $14.38.
Bioventus Company Profile
(
Get Free Report)
Bioventus Inc a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's portfolio of products includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products.
Further Reading
Before you consider Bioventus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bioventus wasn't on the list.
While Bioventus currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access